Core Viewpoint - Chao Yan Co., Ltd. has shown a positive financial performance with a revenue increase of 15% year-on-year and a net profit growth of 18.5% for the first half of 2025, indicating strong operational capabilities and market demand [2]. Financial Performance - For the period from January to June 2025, Chao Yan Co., Ltd. achieved a revenue of 184 million yuan, reflecting a year-on-year growth of 15% [2]. - The net profit attributable to the parent company for the same period was approximately 68.45 million yuan, which represents an 18.5% increase compared to the previous year [2]. - Cumulative cash dividends distributed by the company since its A-share listing amount to approximately 43.69 million yuan [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders for Chao Yan Co., Ltd. was 22,300, a decrease of 16.65% from the previous period [2]. - The average number of circulating shares held per shareholder increased by 19.98% to 2,456 shares [2]. - The top circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.91 million shares as a new shareholder [2]. Trading Activity - On September 24, 2025, Chao Yan Co., Ltd. saw a stock price increase of 1.52%, with a trading volume of approximately 48.73 million yuan [1]. - The financing buy-in amount for the same day was 2.94 million yuan, while the financing repayment was 10.16 million yuan, resulting in a net financing outflow of 7.22 million yuan [1]. - The total balance of margin trading for Chao Yan Co., Ltd. as of September 24, 2025, was approximately 102 million yuan, accounting for 7.03% of its market capitalization [1].
超研股份9月24日获融资买入293.90万元，融资余额1.02亿元